LSM

Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Retrieved on: 
Saturday, March 18, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, JAK1, American Academy, LSM, Patient, AAD, Week, Safety, American Academy of Dermatology, Pharmaceutical industry

Incyte (Nasdaq:INCY) today announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.
  • Results from the study demonstrate that treatment with oral povorcitinib was associated with substantial total body repigmentation in patients with extensive nonsegmental vitiligo, as measured by total Vitiligo Area Scoring Index (T-VASI) scores.
  • “Vitiligo is a chronic, immune-mediated disease which, until recently, had limited treatment options available to patients.
  • “As vitiligo can impact patients in different ways, I am encouraged by the continued focus on expanding medical treatment options, and I believe these data highlight the potential of this investigational oral treatment for patients with extensive nonsegmental vitiligo.”

Ace Vision Group Appoints Cristos Ifantides M.D., MBA as Director, Clinical Applications Development

Retrieved on: 
Thursday, February 23, 2023
Aurora, Wills Eye Hospital, School, Sue, University, University of Colorado School of Medicine, Eye, MBA, National Institute for Health and Care Research, Biological engineering, VESA, Drug development, 3D, Research, AVG, Patient, Mount Sinai Hospital, Mount Sinai Hospital (Manhattan), Cataract, Laser, Surgeon, DPT, Health, Micropore particle technology, Presbyopia, College of Engineering (KNUST), Education, LSM, Medical device, Nursing, Hospital, Ophthalmology

BOSTON, Feb. 23, 2023 /PRNewswire/ -- Ace Vision Group, Inc, (AVG) an emerging ophthalmic device company focused on bringing innovative touchless lasers to patients suffering from age-related vision loss and eye diseases caused by ocular rigidity, announced the appointment of Cristos Ifantides, M.D., MBA as Director, Clinical Applications Development effective immediately.

Key Points: 
  • BOSTON, Feb. 23, 2023 /PRNewswire/ -- Ace Vision Group, Inc, (AVG) an emerging ophthalmic device company focused on bringing innovative touchless lasers to patients suffering from age-related vision loss and eye diseases caused by ocular rigidity, announced the appointment of Cristos Ifantides, M.D., MBA as Director, Clinical Applications Development effective immediately.
  • In his new role as Director, Clinical Applications Development, Dr. Ifantides will lead the education and clinical adoption efforts of AVG's forthcoming presbyopia technology platform.
  • Ifantides will spearhead efforts to continue development of the VESA® digital diagnostics artificial intelligence clinical platform.
  • VESA also has broader applications in virtual clinical simulations which could improve technology assisted research validation and test the efficacy of therapeutic interventions in virtual clinical settings.

Avalon GloboCare Announces Closing of Strategic Investment in Laboratory Services MSO, a Leading Clinical Diagnostics and Reference Laboratory Company

Retrieved on: 
Monday, February 13, 2023
Toxicology, Laboratory, Pharmacogenomics, Celltech, LSM, Cyprus Securities and Exchange Commission, Pathology, National Health Laboratory Service, Genetic testing, STAT, Niche market, Earnout

FREEHOLD, N.J., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it has acquired a 40% interest in Laboratory Services MSO, LLC (“LSM”), a premier clinical diagnostics and reference laboratory. Headquartered in Costa Mesa, California, LSM provides a broad portfolio of diagnostic tests including drug testing, toxicology, pharmacogenetics, and a broad array of test services, from general bloodwork to anatomic pathology. Specific capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, sexually transmitted disease testing and more. LSM has a sophisticated and state-of-the-art facility for clinical diagnostics and reference laboratory. It has also developed a premier reputation for customer service satisfaction and fast turnaround time in the industry. LSM has completed over 600,000 tests since inception and currently has two operational locations in California.

Key Points: 
  • FREEHOLD, N.J., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it has acquired a 40% interest in Laboratory Services MSO, LLC (“LSM”), a premier clinical diagnostics and reference laboratory.
  • Specific capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, sexually transmitted disease testing and more.
  • LSM has a sophisticated and state-of-the-art facility for clinical diagnostics and reference laboratory.
  • It has also developed a premier reputation for customer service satisfaction and fast turnaround time in the industry.

Independent review by network analytics and simulation firm FNA reveals "powerful liquidity savings" generated by CHIPS settlement algorithm

Retrieved on: 
Wednesday, February 1, 2023
CHIPS, Private sector, School corporal punishment, Clearing house, FNA, Literature, Leg, LSM, Senior, USD, New product development, TCH, The Clearing House, Environment, Bank, Mobile phone

LONDON, Feb. 1, 2023 /PRNewswire/ -- London-based deep tech firm FNA, specialising in advanced network analytics and simulation, has revealed the "powerful liquidity savings" generated by CHIPS, the largest private sector high-value clearing and settlement system in the world operated by The Clearing House, following an independent review.

Key Points: 
  • LONDON, Feb. 1, 2023 /PRNewswire/ -- London-based deep tech firm FNA , specialising in advanced network analytics and simulation, has revealed the "powerful liquidity savings" generated by CHIPS, the largest private sector high-value clearing and settlement system in the world operated by The Clearing House, following an independent review.
  • FNA's review of the liquidity savings mechanism (LSM) utilised by CHIPS confirmed CHIPS is "extremely efficient" in its use of liquidity across all performance metrics, when compared to other large-value payment systems.
  • Its patented liquidity savings algorithm matches and offsets payments continually, resulting in a more efficient settlement process.
  • Not only has this validated CHIPS' liquidity efficiency, but also provided TCH with opportunities to improve their system further".

Independent review by network analytics and simulation firm FNA reveals "powerful liquidity savings" generated by CHIPS settlement algorithm

Retrieved on: 
Wednesday, February 1, 2023
CHIPS, Private sector, School corporal punishment, Clearing house, FNA, Literature, Leg, LSM, Senior, USD, New product development, TCH, The Clearing House, Environment, Bank, Mobile phone

LONDON, Feb. 1, 2023 /PRNewswire/ -- London-based deep tech firm FNA, specialising in advanced network analytics and simulation, has revealed the "powerful liquidity savings" generated by CHIPS, the largest private sector high-value clearing and settlement system in the world operated by The Clearing House, following an independent review.

Key Points: 
  • LONDON, Feb. 1, 2023 /PRNewswire/ -- London-based deep tech firm FNA , specialising in advanced network analytics and simulation, has revealed the "powerful liquidity savings" generated by CHIPS, the largest private sector high-value clearing and settlement system in the world operated by The Clearing House, following an independent review.
  • FNA's review of the liquidity savings mechanism (LSM) utilised by CHIPS confirmed CHIPS is "extremely efficient" in its use of liquidity across all performance metrics, when compared to other large-value payment systems.
  • Its patented liquidity savings algorithm matches and offsets payments continually, resulting in a more efficient settlement process.
  • Not only has this validated CHIPS' liquidity efficiency, but also provided TCH with opportunities to improve their system further".

CAI Awarded Prestigious Public Affairs Council Award for Condominium Safety Policy Response and Initiatives

Retrieved on: 
Thursday, February 9, 2023
Fortune 500, Policy, Brilliance Auto Group, Rapids, Public policy, Education, Housing, Safety, Debbie Wasserman Schultz, Feeding America, Memory, CAI, Church, Government, Community Associations Institute, SAFER, Conference, Local government, Trustee, CAE, Public Affairs Council, PCAM, LSM, Organization, PAC, Research, CMCA, Public Affairs Committee (Malawi), Property management, Insurance

Falls Church, Va., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Community Associations Institute (CAI) is honored to receive the 2022 Lobbying Strategy Innovation Award for its condominium safety policy response and initiatives by the Public Affairs Council (PAC).

Key Points: 
  • Falls Church, Va., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Community Associations Institute (CAI) is honored to receive the 2022 Lobbying Strategy Innovation Award for its condominium safety policy response and initiatives by the Public Affairs Council (PAC).
  • Following the tragic partial collapse of Champlain Towers South condominium in Surfside, Fla., in June 2021, CAI released its Condominium Safety Public Policy Report .
  • The Condominium Safety Public Policy Report provides extensive policy positions and recommendations in reserve studies and funding, building maintenance, and structural integrity.
  • For more information on CAI’s condominium safety policy response and resources to the tragic Champlain Towers South condominium collapse, visit www.condosafety.com .

Ace Vision Group Appoints Healthcare Veterans to Lead Business Development and Commercial Teams

Retrieved on: 
Thursday, January 19, 2023
Dynamic range, Ophthalmology, Presbyopia, Alcon, Bascom Palmer Eye Institute, Laser, DPT, Marketing, AVG, Therapy, Patient, Allergan, D1 Capital Partners, Eye, LSM, Pharmaceutical industry, Management, George Frantzis

BOSTON, Jan. 19, 2023 /PRNewswire/ -- Ace Vision Group, Inc, (AVG) an emerging ophthalmic device company focused on bringing innovative touchless lasers to patients suffering from age-related vision loss and eye diseases impacted by ocular rigidity, announced multiple executive appointments today. John Frantzis will serve as Chief Business Development Officer and Alex Lopez will serve as Chief Commercial Officer effective January 19, 2023.

Key Points: 
  • John Frantzis will serve as Chief Business Development Officer and Alex Lopez will serve as Chief Commercial Officer effective January 19, 2023.
  • "I have great respect for the accomplishments of both Mr. John Frantzis and Mr. Alex Lopez in each of their longstanding careers in healthcare.
  • As Chief Business Development Officer, Frantzis will lead AVG 's strategic venture capital funding efforts, global business development, distribution, and sales.
  • "My longstanding experience in ophthalmology combined with my experience in aesthetics is perfectly suited to support the corporate and commercial vision of AVG."

Axcella Announces Program Reprioritization and Corporate Restructuring

Retrieved on: 
Thursday, December 15, 2022
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Biotechnology, Therapy, Security (finance), COVID-19, Homeostasis, Recurrence, Fatigue, IND, Regulation, Patient, Science, NASH, COVID, Non-alcoholic fatty liver disease, File, Compte rendu, Disclosure, Disease, FDA, Emms, FAQ, Hinshaw, Risk, Clinical trial, LSM, Safety, Regulation Fair Disclosure, OHE, EMM, Pharmaceutical industry, Long COVID

Axcella will reprioritize its efforts to focus on the significant unmet need and opportunity presented by Long COVID.

Key Points: 
  • Axcella will reprioritize its efforts to focus on the significant unmet need and opportunity presented by Long COVID.
  • Axcella is engaged in ongoing and productive reviews with regulators in the U.S. and Europe, and the company is aiming to advance its Long COVID Fatigue program into a potential registration trial.
  • Axcella will be discontinuing its ongoing Phase 2b clinical trial of AXA1125 in NASH, while keeping the option to revisit this program should resource availability change.
  • In September, Axcella reported positive data from a preplanned interim analysis from their trial of AXA1125 in NASH.

Imbrium Therapeutics Presents Results of a Phase 2 Study of Sunobinop at 33rd American Academy of Addiction Psychiatry Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Mental Health, Clinical Trials, Crave, Doctor of Pharmacy, Sleep, Maintenance, Therapy, Interstitial, Physician, M.A, AAAP, Addiction psychiatry, Conditional sentence, Polysomnography, AUD, Central nervous system, Eileen Brooke, American Academy, PSG, Patient, Prevalence, Somnolence, Alcoholism, Architecture, FDA, Peripheral nervous system, Pain, CI, Wakefulness, Journal of Medicinal Chemistry, NOP, PACS, LSM, Safety, Gene–environment correlation, Preclinical development, Overactive bladder, Anxiety, American Academy of Addiction Psychiatry, Kolla, Pharmaceutical industry, Mare Imbrium, Insomnia

The data were presented in a poster presentation (#76) at the 33rd Annual Meeting and Scientific Symposium of the American Academy of Addiction Psychiatry (AAAP).

Key Points: 
  • The data were presented in a poster presentation (#76) at the 33rd Annual Meeting and Scientific Symposium of the American Academy of Addiction Psychiatry (AAAP).
  • Sunobinop is an internally discovered oral compound being evaluated as a potential treatment for multiple disorders including insomnia during recovery from AUD.
  • The Phase 2 randomized, double-blind, multi-center, placebo-controlled, parallel-group clinical study enrolled 114 people experiencing insomnia during recovery from AUD.
  • Imbrium is a clinical-stage biopharmaceutical company dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics.

WTW collaboration with Liberty Specialty Markets and Markel moves insurance industry closer to digital-first marketplace

Retrieved on: 
Thursday, November 17, 2022
WTW, Markel Corporation, Digital, LSM, Risk, Insurance, Workforce, Automation, Shoulder, Global production network, Risk management, Financial services

LONDON, Nov. 17, 2022 (GLOBE NEWSWIRE) -- WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company, has announced a new collaboration with insurers Liberty Specialty Markets (LSM) and Markel, launching the pilot phase of an innovative digital commercial insurance platform.

Key Points: 
  • LONDON, Nov. 17, 2022 (GLOBE NEWSWIRE) -- WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company, has announced a new collaboration with insurers Liberty Specialty Markets (LSM) and Markel, launching the pilot phase of an innovative digital commercial insurance platform.
  • Developed in collaboration with LSM and Markel, this new platform signals a step-change in digital trading, especially in a market as complex as London.
  • At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital.
  • Liberty Specialty Markets offers specialty and commercial insurance and reinsurance products across key UK, European, Middle East, US, Bermuda, Asia Pacific & Latin America markets.